

AMOEBA informs on the adoption by the Biocidal Products Committee of the non-approval of the active substance

Lyon, 26th April 2018 - AMOEBA (FR0011051598 - AMEBA), producer of a biological biocide capable of eliminating the risk of waterborne bacteria, announces that the dossier for approval of its active substance *Willaertia magna C2c Maky* for use in product-type 11 (PT 11 - Preservatives for liquid-cooling and processing systems) has been discussed during the Biocidal Products Committee session of April 26th, 2018.

The Biocidal Products Committee adopted opinion is the non-approval of the active substance *Willaertia magna C2c Maky* for the use in PT 11.

This opinion will have to be confirmed by the European Commission through an implementing regulation. The implementing regulation is expected during the fourth quarter of 2018.

The European Commission is not legally bound to follow the Biocidal Products Committee's opinion. If the European Commission confirms the Biocidal Products Committee opinion, the Company will make all efforts to preserve its rights. In particular, the Company will file an action for the annulment of the decision in front of the European competent courts, together with a request to suspend the decision. The suspension could take effect rapidly following the publication of the implementing regulation.

"I cannot understand this opinion in view of the elements of the dossier and the absence of confirmed risk. During the European peer-review, the Working Group experts provided many positive elements in favor of our dossier, however the French ANSES has stubbornly maintained its position, which has served as the basis for the Biocidal Products Committee's opinion. We are already considering to submit a new request to another Member State convinced by our technology and that would support the active substance approval - which has never been done by ANSES", states Fabrice PLASSON, **Managing Director of AMOEBA.**



About AMOEBA:

Amoéba's ambition is to become the world leader in the treatment of waterborne bacterial risk, wound care and plant protection. Our BIOMEBA solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn ⁽¹⁾ on a global chemical biocide market for water treatment, evaluated at €21Bn ⁽²⁾. In the future, the Company is looking at developing new applications such as chronic wound care, estimated at € 751 million ⁽³⁾ in the USA, and the biocontrol market for plant protection estimated globally at €1.6Bn ⁽⁴⁾. Sales of the BIOMEBA product for use in industrial cooling towers is subject the Company being granted local regulatory market authorizations.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on the compartment C of Euronext Paris. The Company is a member of the BPIfrance Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on www.amoeba-biocide.com.

(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013

(2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et MarketsandMarkets

(3): BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017

(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts :

Amoéba

Nathalie COMBROUSSE
Marketing Communication Manager
Tel : (+33)4 81 09 18 15
nathalie.combrousse@amoeba-biocide.com

Actifin

Ghislaine GASPARETTO
Investors communication
Tel. : (+33)1 56 88 11 11
ggasparetto@actifin.fr

Disclaimer

This press release contains certain forward-looking statements concerning AMOEBA which are based on its own assumptions and hypothesis and on information that are available to us. However, AMOEBA gives no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of AMOEBA filed with the French Financial Markets Authority (*Autorité des Marchés Financiers*) on April 25, 2017 (a copy of which is available on www.amoeba-biocide.com). The forward-looking statements contained in this press release are also subject to risks not yet known to AMOEBA or not currently considered material by AMOEBA. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of AMOEBA to be materially different from such forward-looking statements.